➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Express Scripts
Dow
Harvard Business School
Merck

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,173,881


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,173,881 protect, and when does it expire?

Patent 9,173,881 protects UPTRAVI and is included in one NDA.

This patent has forty-five patent family members in twenty-seven countries.

Summary for Patent: 9,173,881
Title:Therapeutic compositions containing macitentan
Abstract: The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof. ##STR00001##
Inventor(s): Clozel; Martine (Binningen, CH)
Assignee: ACTELION PHARMACEUTICALS LTD. (Allschwil, CH)
Application Number:14/335,657
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,173,881

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Actelion UPTRAVI selexipag TABLET;ORAL 207947-001 Dec 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ⤷  Try it Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-002 Dec 21, 2015 RX Yes Yes ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ⤷  Try it Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ⤷  Try it Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-004 Dec 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ⤷  Try it Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-005 Dec 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ⤷  Try it Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-006 Dec 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ⤷  Try it Free
Actelion UPTRAVI selexipag TABLET;ORAL 207947-007 Dec 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,173,881

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/IB2008/053252Aug 13, 2008

International Family Members for US Patent 9,173,881

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 073031 ⤷  Try it Free
Australia 2009280843 ⤷  Try it Free
Brazil PI0917661 ⤷  Try it Free
Canada 2731370 ⤷  Try it Free
China 102099026 ⤷  Try it Free
Cyprus 1119826 ⤷  Try it Free
Denmark 2315587 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Mallinckrodt
Express Scripts
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.